Agmatine

Clinical Summary

Agmatine is decarboxylated L-arginine, an endogenous neuromodulator produced in small amounts by human tissues and by gut microbiota. It is sold OTC as agmatine sulfate for three overlapping audiences: chronic neuropathic-pain sufferers (the only indication with a human RCT), bodybuilders using it pre-workout for "pump" (no human RCT supports this), and nootropic/harm-reduction communities using it to blunt opioid and kratom tolerance (robust rodent data, zero human trials).

Its pharmacology is genuinely polypharmacological: non-competitive NMDA receptor antagonism (GluN2B-preferring), α2-adrenergic and imidazoline I1/I2 binding, nNOS/iNOS inhibition, and modulation of the polyamine and agmatinase pathways. This breadth explains both why neuropathic-pain and opioid-tolerance effects make mechanistic sense and why causal claims for any single indication are hard to prove.

The human evidence base is thin and severely conflicted. Every efficacy trial for pain was authored or co-authored by Gilad & Gilad LLC (PMID 20447305, 32102167, 25247837), the company that sells the trademarked AgmaSet / G-Agmatine form. No independent lab has replicated the neuropathic-pain findings in the 16 years since Keynan 2010. No Cochrane review, no medical society guideline, and no human meta-analysis exist. BioMCP FAERS returns 6 reports, all confounded by co-administered drugs (isotretinoin, adalimumab, enoxaparin, insulin, kratom) — a reliable null signal for serious harm, but one that reflects OTC-supplement underreporting more than established safety.

Two novel 2024 mouse-model findings deserve explicit attention: microbial agmatine driving PCOS via FXR-GLP-1 suppression (PMID 38769396, Nature Metabolism) and microbial agmatine promoting colorectal tumorigenesis via Wnt/β-catenin (PMID 38706224, Gut Microbes). Both describe endogenous bacterial agmatine as a disease driver, not oral supplementation as a toxicant — but they indicate agmatine biology is mechanistically bidirectional, not uniformly beneficial.

The honest summary: agmatine has meaningful reasons to suspect benefit in neuropathic pain and opioid-tolerance contexts, one unreplicated RCT and one open-label series at its best, zero guideline endorsement, and newer preclinical data raising condition-specific caution flags. It is a reasonable candidate for time-limited self-experimentation in a documented neuropathic-pain case with informed consent about the thinness of the evidence — and a poor candidate as a general-use nootropic or pre-workout supplement despite aggressive marketing in both categories.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (legend below). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type.

Type codes: DC=Direct causation | PC=Probable causation | UCC=Unreplicated causal (single trial, no replication) | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human extrapolation | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence

BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none

Safety flags: -- No signals | MON Monitor (known manageable AEs: GI at higher dose) | WARN Pre-clinical safety signal for this indication pathway (see Safety) | AVOID Contraindicated for this specific indication

Prose notes on specific indications

Lumbar disc radiculopathy (Keynan 2010, PMID 20447305): The strongest human trial. Double-blind RCT, N=99 randomized (51 agmatine / 48 placebo), analyzed N=61 after ~38% attrition. Dose 2.67 g/day × 14 days. Results reported as percent-of-baseline improvement (atypical; usually absolute mean differences with CIs are preferred): 26.7% pain ↓ (agmatine) vs 6.0% (placebo), 70.8% vs 20.0% QoL gain (SF-36), both p≤0.05. Authors Gilad GM and Gilad VH are the commercial suppliers. Never independently replicated in 16 years. Star ceiling: 3/5 not 4/5 because it is one small unreplicated trial with COI.

Small-fiber neuropathy (Rosenberg 2020, PMID 32102167): Open-label, no control, no blinding, N=11 completers. 2.67 g/day × 2 months. Mean pain ↓ 46.4% on 12-item NPQ; "all 11 patients improved." This is not definitive — no placebo arm, small N, Gilad co-author. Published in Nutrients (MDPI, lower editorial rigor). Cannot separate regression-to-the-mean, expectation, or natural course. Star ceiling: 2/5 (UCC).

Depression pilot (Shopsin 2013, PMID 25287313): N=3 MDD, all remitted. Abstract lists dose as "2-3 mg/day" — almost certainly a typo for g/day; full-text verification recommended before using. Mechanism probe included PCPA challenge, which did not reverse remission, suggesting non-serotonergic antidepressant pathway. N=3 is signal-level only.

Surprising omission — exercise performance: Zero human RCT data exist for any muscle-performance or pump endpoint despite this being one of the heaviest marketing channels for agmatine since ~2012. The pump claim rests entirely on extrapolation from arginine→NO biochemistry and animal polyamine literature. Folk consensus reports a pump effect, but the typical formulation (agmatine + citrulline or arginine) competes at the cationic transporter (PMID 15028572), likely reducing agmatine absorption per the product's own stack. This is the largest evidence-vs-marketing gap in the agmatine ecosystem.

Prescribing

Dosing Table

Formulation Table

Cost for clinical 2.67 g/day protocol: ~$45-90/month depending on vendor and capsule vs powder format. Powder is more economical but bitter; capsules require 4-6 per day at typical 500-750 mg strengths.

Food effect: Gilad protocol specifies "after meals." No formal fed-fasted PK study in humans. Taking with food is reasonable on first principles (fermented foods provide endogenous dietary precedent) and to reduce GI upset at higher doses.

The "1% oral bioavailability" myth: Widely repeated on bodybuilding and supplement forums. Originates from misattribution. Validated rat PK (Clements 2023, PMID 37770201) shows 29-35% oral bioavailability. No human PK study exists, so the true human number is unknown, but "1%" is not correct.

Condition-Specific Protocols

Lumbar Disc Radiculopathy Protocol

Evidence: 3/5 | PMID 20447305 (Keynan 2010, the only human RCT)

Phase 1: Initiation (Days 1-3)

• Dose: 2.67 g/day agmatine sulfate, split 3 × ~890 mg after meals
• Watch for: GI upset (nausea, loose stool). If intolerable, drop to 1.78 g/day × 3 days then titrate back up.
• Goal: establish tolerance before full therapeutic period.

Phase 2: Therapeutic (Days 4-14)

• Dose: 2.67 g/day maintained, split 3 × ~890 mg
• Monitor weekly: VAS pain, Oswestry Disability Index self-score, any new AEs
• Expected trajectory: per Keynan, measurable improvement by day 14; effect size modest (26.7% percent-of-baseline improvement in pain).

Phase 3: Reassessment (Day 14+)

• If clinically meaningful improvement (≥30% pain reduction): continue at 2.67 g/day. Keynan trial was only 14 days; long-term pain efficacy beyond this window is not established in trial data.
• If no improvement after 14 days: discontinue; agmatine is unlikely to help.
• No controlled data support extending > 2 weeks in this indication; folk reports suggest effect persists only while dosing.

Drug Interaction Timing: Space from clonidine, guanfacine, or other α2-agonists by at least 2 hours to manage additive central α2/I1 effects. If on SSRIs or MAOIs, discuss with prescribing physician before starting; theoretical serotonin overlap is unstudied in humans.

Expected Outcomes: ~27% percent-of-baseline pain reduction (agmatine arm); placebo arm ~6%. SF-36 QoL gain ~71% vs 20% placebo. These are percent-of-baseline, not absolute point differences — clinical magnitude remains modest.

Stop/Reassess Criteria: Persistent GI effects after dose reduction; BP drop or dizziness; no improvement at day 14; worsening radicular signs (consult surgeon).

Small-Fiber Neuropathy Protocol

Evidence: 2/5 | PMID 32102167 (Rosenberg 2020, N=11 open-label, no control)

Phase 1: Initiation (Weeks 1-2)

• Dose: 2.67 g/day split 3 doses after meals
• Watch for: GI upset; autonomic symptom flares (SFN patients often have autonomic dysfunction — monitor postural BP, HR).
• Goal: tolerance + baseline symptom diary (12-item NPQ self-score weekly).

Phase 2: Therapeutic (Weeks 3-8)

• Dose: 2.67 g/day maintained
• Monitor monthly: NPQ score, HR variability if tracking, pain quality changes (burning, tingling, numbness scored separately), concomitant med doses (some users reduce gabapentin under clinician guidance — do NOT self-reduce without prescriber involvement)
• Expected: Rosenberg reported all 11 patients improved; mean ~46% NPQ reduction at 2 months. Plausibility moderated by open-label, no control.

Phase 3: Maintenance (Week 8+)

• No controlled data beyond 2 months. Gilad 2014 self-case report describes 4-5 years at 2.67 g/day with no AEs — but N=2 and the authors are the suppliers.
• Rosenberg noted effects fade if agmatine is stopped (short half-life, no nerve regeneration) → ongoing dosing required if continuing.
• Reassess every 3 months: if benefit sustained, continue; if plateau then decline, try a 2-week washout to test whether benefit is durable.

Drug Interaction Timing: Same as radiculopathy protocol. Special care with insulin/sulfonylureas — agmatine-FXR-GLP-1 axis (preclinical) and some rodent hypoglycemia data suggest cautious glucose monitoring in diabetic SFN patients.

Expected Outcomes: ~46% mean NPQ reduction (open-label, no control — real effect size likely smaller). Burning pain subscale shows largest drops in Rosenberg data.

Stop/Reassess Criteria: No improvement at 2 months; new autonomic instability; significant BP drop; persistent GI effects; significant appetite/metabolic changes (preclinical FXR-GLP-1 signal in females).

Safety

Interactions Table

Contraindications

• Pregnancy and lactation. Zero human safety data. Agmatine is present in human breast milk (endogenous), but exogenous supplementation has no human reproductive safety evaluation. Precautionary contraindication.
• Active PCOS or documented insulin resistance in women — precautionary, driven by 2024 mouse data showing microbial agmatine drives PCOS phenotype via FXR-GLP-1 / GLP-1 suppression (PMID 38769396). Not a proven human effect, but a specific-population caution.
• Personal or strong family history of colorectal cancer — precautionary, driven by 2024 mouse data on microbial agmatine promoting CRC via Wnt/β-catenin (PMID 38706224). Not a demonstrated human supplement risk, but the mechanism raises a condition-specific flag.
• Known hypersensitivity to agmatine sulfate.
• Severe hepatic impairment — precautionary, given very high first-pass liver accumulation (~67% of oral dose in rat, PMID 15028569) and rodent data showing oral agmatine impairs liver regeneration after partial hepatectomy.
• Concurrent MAOI therapy — theoretical interaction.

Adverse Effects (ranked by frequency)

FAERS Signal Table (from BioMCP)

Total FAERS reports: 6. All 6 reports list agmatine as concomitant/co-reported rather than suspect drug. Primary suspects across the 6 reports: isotretinoin, adalimumab, enoxaparin, insulin glargine, and kratom/mitragynine-containing products. Reliable null signal for serious harm from oral agmatine supplementation, but this reflects OTC-supplement FAERS underreporting more than established safety. No indication-relevant signal clusters.

Monitoring Table

Special Populations

Renal Impairment

Hepatic Impairment

Pregnancy / Lactation

No human data. Precautionary contraindication. One rodent study (PMID 37269159) showed agmatine given to pregnant mice ameliorated offspring cognitive deficits from maternal stress (beneficial), but this does not establish safety for supplementation in human pregnancy. Agmatine is endogenously present in breast milk.

Pediatric Use

Single adolescent observational cohort (PMID 39420609, Yazici 2024) found adolescent MDD patients had elevated plasma agmatine as biomarker — not an intervention study. No pediatric supplementation trials exist. Avoid in children unless under specialist supervision.

Synergies & Stacking

Known antagonism / caution:

• High-dose L-arginine + L-citrulline: compete with agmatine at cationic transporter → reduced agmatine absorption. Many commercial pre-workouts pair them, which likely reduces agmatine's usable dose.
• Clonidine / guanfacine: additive central α2/I1 effect — potential over-sedation or hypotension.

Individual Response Modifiers

Sex-Specific Considerations

Study population bias: Rosenberg 2020 cohort was mixed-sex small-fiber neuropathy patients; Keynan 2010 radiculopathy cohort sex distribution not prominently reported; rodent pain and depression studies span both sexes with inconsistent sex-split reporting. Dosing has not been studied separately by sex.

Genetic Modifiers

Bottom line: No actionable pharmacogenomic tests are validated for agmatine. The variant catalog commonly used for supplements (MTHFR, VDR, COMT, APOE, CYP2D6) has no demonstrated relevance to agmatine response. Agmatine is not extensively CYP-metabolized — renal excretion is the primary clearance route.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent.

Dominant Sentiment

Mixed-to-positive, polarized by use case. Strongly positive for kratom tolerance and pre-workout pumps (with caveat); mixed for opioid-tolerance reset; cautiously positive for chronic pain and anxiety; wear-off-prone for depression.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: None specific to agmatine.
• Influencer concentration: Low-to-moderate. No single dominant YouTube voice. Agmatine has flown under the radar of the "intellectual biohacker" tier (no Gwern, Rhonda Patrick, Attie, SuppVersity deep dive).
• Astroturfing signals: Moderate. Some clustered iHerb/Amazon review language on specific listings. Multiple vendor pre-workout brands (Agmatine XT, RC Pump, Agmatine Supreme) drive pump-review ecosystem.
• Commercial bias: High in the bodybuilding/pre-workout coverage — Tiger Fitness, MRI Performance, AllMax, 4 Gauge, NutraBio, Hugesupplements, Transparent Labs, Gaspari, Russ Howe PTI. Affiliate-heavy.
• Vendor sourcing of clinical evidence: The clinical efficacy trials themselves come from the commercial supplier (Gilad & Gilad LLC). This is not community hype — it is the primary literature.
• Viral forum threads: Legacy threads like UncleWade's "Welcome to PUMP CITY" drove disproportionate early hype on Bodybuilding.com.

Folk vs Clinical Reality Check

Folk evidence aligns with clinical data in exactly two domains: (1) neuropathic pain at 2.67 g/day — both the published RCT (Keynan 2010) and open-label series (Rosenberg 2020) and the community converge on this dose and a modest real effect; (2) opioid/morphine tolerance attenuation, where robust rodent data and large forum N (Bluelight, Drugs-Forum) parallel each other despite zero human clinical trial. Folk evidence diverges from clinical in the pre-workout pump claim — no human performance trial supports it, and formulation logic argues the typical citrulline+agmatine pre-workout stack is self-defeating at the cationic transporter; the pump claim appears largely affiliate-driven. Folk evidence is picking up real effects that clinical has not tested in two areas: (a) kratom tolerance modulation — NMDA-mechanism-plausible, massive community N, but essentially zero clinical study, and (b) benzodiazepine withdrawal support, where rodent data supports the community practice but no human trial exists.

Deep Dive: Mechanisms & Research

Confirmed or supported in humans

• Pain modulation via NMDA antagonism: Indirect support — Keynan 2010 radiculopathy RCT is consistent with NMDA-mediated central sensitization being the target. Not directly measured in humans. PMID 20447305, 37770201 (GluN2B rationale).
• Imidazoline I1 receptor binding: Human platelet I1 density correlates with plasma agmatine in depressed patients (PMID 10415948). Best available human receptor-level evidence.
• Plasma and CSF presence: Human CSF 24.3-54.0 ng/mL, plasma 8.4-65.1 ng/mL (PMID 19296353). Weak plasma-CSF correlation — peripheral and central compartments partially distinct.

Strong preclinical, awaiting human confirmation

• α2-adrenergic agonism (PMID 22212617, 40721346, 17927294)
• nNOS / iNOS inhibition (PMID 17927294, 31518574, 40243752)
• Polyamine pathway modulation via agmatinase → putrescine and competition with ODC (PMID 11914032, 29162499, 39924644)
• KATP channel modulation in rodent analgesia/anticonvulsant models (Molderings review, PMID 22212617)
• 5-HT1B / 5-HT2A upregulation in dorsal raphe (PMID 40243752, 2025)
• Mitochondrial dynamics and microglial glycolysis (PMID 39890051, 39888089)
• NF-κB / TNF-α suppression and macrophage M1→M2 polarization (PMID 25243152, 39413617)

Novel mechanisms raising caution (2024+)

• FXR agonism → GLP-1 suppression → insulin resistance / PCOS in female mice, microbial agmatine as driver (PMID 38769396, Nature Metab 2024)
• Wnt/β-catenin promotion via Rnf128 binding → colorectal tumorigenesis in mouse model, microbial agmatine as driver (PMID 38706224, Gut Microbes 2024)
• LTP suppression in healthy hippocampal tissue (not just rescue in Aβ-damaged tissue) (PMID 40721346, 2025) — nuance for the "pro-cognitive" framing

Pharmacokinetics (rat)

• Oral bioavailability 29-35% (PMID 37770201, Clements 2023) — contradicts the "1%" forum claim
• IV plasma half-life ~15-19 min; oral half-life ~74-117 min (flip-flop kinetics)
• Crosses blood-brain barrier; brain accumulation higher than spinal cord after IV
• ~67% of oral dose concentrates in liver in radiolabel tracer studies (PMID 15028569)
• Primary elimination: renal excretion of unchanged agmatine

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Zero active or recruiting trials. Zero trials registered outside these three. NCT00405041 is discoverable only by NCT number because the intervention is cloaked as "Dietary supplement GVG 2" on ClinicalTrials.gov.

Regulatory Status (from BioMCP)

• FDA: Not an approved drug. Sold as dietary supplement under DSHEA. An NDI notification was accepted for Gilad & Gilad LLC's form (AgmaSet / G-Agmatine).
• EMA: Not authorized as medicinal product. Not on the EU Novel Food register as a generally authorized novel food.
• TGA (Australia): Not on AUST L permitted-ingredient schedule.
• Health Canada: Permissible in licensed NHPs under structure-function claims; no specific monographed claim.
• Romania / EU: Supplement category under national food-supplement framework.
• Japan: Endogenous precedent via Aspergillus oryzae-fermented foods (miso, soy sauce, sake, mirin). Supplement category.
• Regulatory context: Agmatine is off-patent (endogenous human metabolite), has no commercial drug-development pipeline, and has never been submitted to any regulator for a drug indication. The regulatory silence reflects commercial non-viability as a drug, not a known safety issue.

Ataraxia Verdict (as of 2026-04-24)

Evidence Classification (Mode 5)

Hype Check (Mode 1)

• Appeal to nature: "Endogenous amine, your body makes it, so it's safe at any dose" — endogenous ≠ safe at exogenous therapeutic doses.
• Hasty generalization (animal → human): The entire pre-workout, opioid-tolerance, and anti-depressant literature in marketing leans heavily on rodent work without naming it as such.
• Appeal to authority via a single research group: Every positive human efficacy paper (Keynan 2010, Rosenberg 2020, Gilad 2014, Molderings 2012 review) involves Gilad or the supplier. Citation density hides citation concentration.
• Cherry-picking: Vendor blogs list the positive rodent findings and omit the 2024 adverse mechanism papers (PCOS, CRC) and the LTP-suppression nuance.
• Argument from popularity: "Used by millions of biohackers" — confuses commercial reach with evidence.
• Bioavailability myth: "1% oral bioavailability" is commonly repeated to explain underperformance and justify higher doses; rat data shows 29-35%.

Evidence Gaps

• Zero independent replication of Keynan 2010 in 16 years. No lab outside Gilad's collaborators has confirmed the radiculopathy RCT.
• Zero human pharmacokinetic study. All PK inferences are rodent-to-human.
• Zero human performance / muscle / pump trials despite this being the dominant commercial market.
• Zero Cochrane review, zero medical society guideline mentions agmatine anywhere in pain, depression, or sports-nutrition literature as of 2026-04.
• Zero pregnancy/lactation human safety data.
• No head-to-head RCT with gabapentinoids, NMDA antagonists, or α2-agonists.
• No sex-stratified human efficacy analysis.
• No pharmacogenomic test validated.

Bias Flags (Mode 4)

• Commercial-supplier authorship of all human efficacy trials. The single most important bias in the agmatine literature. This is not a hidden conflict — it is declared — but the concentration is unusual.
• MDPI / lower-editorial-rigor venue for Rosenberg 2020 (Nutrients).
• Percent-of-baseline outcome reporting in Keynan 2010 — atypical for pain RCTs, favorable to the intervention.
• High attrition (~38%) unexplained in Keynan 2010 analysis.
• Unblinded investigators in the 2014 self-case-report (N=2 authors).
• Publication bias asymmetry: rodent positive findings are heavily published; negative rodent findings (e.g., LTP suppression in healthy tissue, FXR-GLP-1 adverse signal) are newer and less frequently cited in consumer-facing content.

Manipulation Flags (Mode 2)

• Industry marketing: The pre-workout supplement industry has extensively marketed agmatine for "pump" and muscle performance since ~2012 despite zero human RCT evidence in this domain. Common patterns include "clinical strength" claims, stack formulations that pair agmatine with citrulline/arginine (which likely reduce its absorption at the cationic transporter), and "proprietary blend" labeling that obscures actual agmatine dose.
• Influencer economics: Low-to-moderate. Affiliate structures are common on bodybuilding and supplement blogs (Tiger Fitness, MRI Performance, Transparent Labs, NutraBio, Gaspari, Hugesupplements). Coverage correlates with affiliate revenue. There is no single dominant YouTube voice driving the category.
• Counter-narrative manipulation: Minimal. Agmatine has no strong pharma competitor with motive to fearmonger. The Cleveland-Clinic-class institutional caution is absent, not suppressed.
• Cui bono summary — who wins if you take it: Gilad & Gilad LLC (the trademarked form), dozens of supplement vendors (generic form), pre-workout brands, kratom vendors who reference it as tolerance solution. Who wins if you don't: Competing supplement categories (citrulline, beta-alanine), prescribers of gabapentinoids for neuropathic pain, and researchers of patentable NMDA modulators. The pro-agmatine economic stake is clearly larger than the anti-agmatine stake.
• Red team highlight (most concerning angle): The entire human efficacy base for chronic use is authored by the commercial supplier with no independent replication in 16 years, AND newer 2024 microbial-agmatine mouse models suggest endogenous agmatine can drive disease (PCOS, CRC). If the commercial suppliers were motivated to withhold or down-weight uncomfortable mechanistic findings, the current consumer-facing literature would look exactly as it does.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 4/10. Compound-intrinsic. Agmatine has a narrow strong-indication (neuropathic pain, single unreplicated RCT), broad but weak preclinical coverage, and newly flagged condition-specific adverse signals. Its pharmacology is genuinely interesting but its human evidence is thin and conflicted. Would score 6/10 for a person with documented SFN or refractory radiculopathy; 2/10 for general-population "nootropic" or pre-workout use.
• Opportunity cost: Moderate. Complexity (3×/day dosing), GI risk at higher doses, cost (~$45-90/month at therapeutic dose), and displacement of attention from treatments with stronger evidence (e.g., gabapentin or duloxetine for neuropathic pain; ALA for diabetic neuropathy).
• Verdict: CONDITIONAL.
• Conditions warranting use:
  1. Refractory lumbar disc radiculopathy after failure of standard conservative management — time-limited 14-day trial per Keynan protocol, with clinician awareness.
  2. Diagnosed small-fiber neuropathy (skin biopsy + autonomic confirmation) unresponsive to gabapentinoids and duloxetine — 2-month trial per Rosenberg protocol, with clinician awareness and baseline metabolic panel.
  3. Documented opioid dependence tapering / kratom tolerance reset — low-dose (250-1000 mg) as harm-reduction adjunct, with explicit understanding that this is folk-evidence-tier.
• Do NOT recommend for: general nootropic use, pre-workout pump claims, depression (insufficient human evidence), women with PCOS/insulin resistance (preclinical FXR-GLP-1 signal), personal or strong family CRC history, pregnancy/lactation, severe hepatic impairment.

Bottom Line

Agmatine is a legitimate pharmacological curiosity with one interesting unreplicated pain RCT, one promising open-label SFN series, a large preclinical foundation, and an aggressive supplement marketing ecosystem that has outrun its evidence. It is defensible as a time-limited trial in documented neuropathic-pain cases and as a harm-reduction adjunct in opioid/kratom contexts. It is not defensible as a general nootropic, pre-workout, or antidepressant. The 2024 microbial-driver papers (PCOS, CRC) add a layer of condition-specific caution that the consumer-facing literature has not yet absorbed. Watch for: an independent replication of Keynan 2010 (would move star rating to 4/5), human pharmacokinetic data, or a randomized trial in SFN. Revisit in 2026-10.

Practical Notes

Brands & Product Selection

• Gilad & Gilad LLC forms (AgmaSet, G-Agmatine): Used in the published clinical trials. Premium priced. Trademark trust high; independent verification of batch purity still advised.
• Reputable third-party-tested bulk brands: NOW Foods, Nutricost, BulkSupplements, PureBulk, Primaforce, Nootropics Depot. Look for COA showing ≥98% agmatine sulfate and heavy-metal panel.
• Red-flag brands: Pre-workout blends with "proprietary blend" agmatine content (dose obscured), brands with no third-party testing, brands bundling agmatine with high-dose citrulline/arginine (transporter competition — the formulation contradicts the marketing).
• CoA requirements: ≥98% agmatine sulfate (not agmatine free base, which is less stable); heavy metals (Pb, As, Cd, Hg) below USP <232> limits; microbial panel; residual solvent panel.
• Fermented-food dietary precedent: Japanese miso, soy sauce, sake, and mirin produced with Aspergillus oryzae contain measurable endogenous agmatine (PMID 30915570, 41655144). Dietary amounts are insufficient for therapeutic dose but support long-term safety at low endogenous exposure.

Storage & Handling

Agmatine sulfate is hygroscopic. Store in sealed container, cool dry dark place. Capsules are stable at room temperature. Bulk powder benefits from a desiccant. No significant light degradation. Shelf life per manufacturer typically 2 years unopened.

Palatability & Compliance

Raw agmatine sulfate powder is notably bitter. Rosenberg 2020 reported 1 of 12 patients discontinued for taste. Mixing strategies: small volume of flavored beverage; chasing with citrus juice; capsule form avoids the taste problem at higher capsule count (4-6 capsules × 500-750 mg for 2.67 g/day). Habit stacking: link to an existing 3×/day routine (meals) to match the post-meal dosing schedule. Consistency matters more than timing precision — agmatine has short half-life and daily compliance drives the effect.

Exercise & Circadian Timing

No exercise-window-specific dose recommendation supported by human RCT data. Folk pre-workout dosing (500-1500 mg, 45-60 min pre-training, empty stomach) is not clinically validated and likely competes with arginine/citrulline in co-administered pump formulas. For therapeutic pain use, split doses with meals (AM + midday + PM). Evening doses ≥2 g have been anecdotally reported to cause paradoxical wakefulness in some users — if insomnia occurs, consolidate dosing to AM + midday.

Reference Ranges (Expected Biomarker Changes)

Cost

• Bulk powder: ~$20-40 per 250 g at reputable vendors → $0.20-0.40/g; therapeutic 2.67 g/day ≈ $0.50-1.10/day, **$15-35/month**.
• Premium capsules (Nootropics Depot 250 mg × 120 ≈ $25-35): ~$0.20-0.30/capsule; 2.67 g/day requires 11 capsules/day at 250 mg → impractical. At 500-750 mg capsules: 4-6 capsules/day → **$45-90/month**.
• AgmaSet / G-Agmatine (trademarked): premium pricing, ~$60-100/month for therapeutic dose.
• Pre-workout blends: agmatine is typically 500-1000 mg per serving, priced at product level; not cost-effective for therapeutic dose.

What We Don't Know

• Whether Keynan 2010's radiculopathy RCT replicates in an independent lab. Sixteen years with no replication attempt is itself informative.
• Human pharmacokinetics at any dose — all PK data are rodent.
• Whether the Rosenberg 2020 open-label SFN finding would survive a placebo-controlled design.
• Long-term safety beyond ~2 months of clinical observation (Gilad 2014 N=2 self-experiment is the only chronic data point).
• Whether the 2024 microbial-FXR-GLP-1 PCOS mechanism translates from mouse to human — or whether oral supplementation reproduces the endogenous microbial signal.
• Whether the 2024 microbial-Wnt/β-catenin CRC mechanism translates to human colorectal risk from supplementation.
• Whether the "pump" claim in bodybuilding has any human-performance validity at all.
• Sex-specific dose-response, pregnancy/lactation safety, pediatric safety.
• Whether pharmacogenomic variants in AGMAT, FXR, or polyamine pathway genes predict response.
• Head-to-head comparative efficacy vs gabapentinoids, duloxetine, or α2-agonists in neuropathic pain.
• Whether fermented-food endogenous intake provides any measurable benefit.

References

Systematic reviews & major reviews

• Manole et al. 2025, Med Sci (Basel) — preclinical cardiovascular systematic review (60 studies, bidirectional BP/HR effects) — PMID 41283257
• Rafi et al. 2024, Neuropeptides — comprehensive pharmacological profile — PMID 38608401
• Katariya et al. 2024, Ageing Res Rev — Alzheimer's review — PMID 38479477
• Zamanian et al. 2025, Inflammation — Parkinson's review — PMID 39225914
• Nibrad et al. 2025, Neuroscience — mitochondrial dynamics review — PMID 39890051
• Saha et al. 2023, Ageing Res Rev — gut microbiome link — PMID 37673131
• Dhaigude et al. 2025, Behav Brain Res — alcohol use disorder review — PMID 40914331
• Akasaka & Fujiwara 2026, J Biosci Bioeng — Aspergillus oryzae agmatine production — PMID 41655144
• Akasaka 2020 — A. oryzae arginine decarboxylase — PMID 30915570
• Piletz et al. 2013, Drug Discov Today — 100 years in translation consensus review — PMID 23769988
• Molderings & Haenisch 2012, Pharmacol Ther — foundational physiological review — PMID 22212617
• Xu et al. 2018, Curr Neuropharmacol — neuroprotection review — PMID 28786346
• Halaris & Plietz 2007, CNS Drugs — CNS spectrum review — PMID 17927294

Human clinical (efficacy)

• Keynan et al. 2010, Pain Med — the pivotal radiculopathy RCT — PMID 20447305
• Rosenberg et al. 2020, Nutrients — small-fiber neuropathy open-label series — PMID 32102167
• Shopsin 2013, Acta Neuropsychiatr — MDD N=3 pilot — PMID 25287313
• Gilad & Gilad 2014, J Med Food — N=2 self-case-report 5-year safety — PMID 25247837

Human observational / biomarker

• Regunathan et al. 2009 — human CSF reference range — PMID 19296353
• Halaris et al. 1999 — plasma agmatine elevated in depression — PMID 10415948
• Uzbay et al. 2013 — plasma agmatine in schizophrenia — PMID 23664672
• Yılmaz et al. 2019 — bipolar mania — PMID 31081413
• Garip et al. 2019 — first-episode psychosis — PMID 30587428
• Esnafoglu 2018 — autism spectrum — PMID 29302750
• Jo et al. 2010 — metabolic syndrome Korean cohort N=322 — PMID 19929601
• Coradduzza et al. 2022 — prostate cancer biomarker — PMID 35454104
• Yazici et al. 2024 — adolescent MDD polyamine panel — PMID 39420609
• Monu et al. 2025 — human glaucoma aqueous humor metabolomics — PMID 40402521
• Bernstein et al. 2012 — agmatinase upregulated in mood disorder postmortem — PMID 21803059

Pharmacokinetics & mechanism

• Clements et al. 2023, J Pharmacol Exp Ther — rat PK + GluN2B-NMDA rationale — PMID 37770201
• Molderings et al. 2003 — gut uptake, liver accumulation — PMID 15028569
• Nguyen et al. 2003 — neuropharmacokinetics central vs systemic — PMID 15028573
• Özbaşak et al. 2025 — DRN 5-HT1B/5-HT2A regulation — PMID 40243752
• Chang et al. 2025 — hippocampal LTP via α2/I1 — PMID 40721346
• Iyer et al. 2002 — human agmatinase cloning — PMID 11914032
• Zhu et al. 2004 — human arginine decarboxylase expression — PMID 14738999
• Benítez et al. 2018 — mammalian agmatine degradation pathways — PMID 29162499
• Sinn et al. 2022 — human agmatinase substrate preference — PMID 36543883
• Yan et al. 2023 — agmatinase bidirectional affective state — PMID 36849038

Preclinical therapeutic — kidney

• Sugiura et al. 2020 — contrast-induced nephropathy — PMID 32999165
• Ishizuka et al. 2000 — anti-thy-1 glomerulonephritis — PMID 11095648
• Azar et al. 2025 — diabetic nephropathy α-Klotho — PMID 40810171

Preclinical therapeutic — CNS

• Song et al. 2014 — STZ-AD rat model — PMID 24719136
• Bilge et al. 2020 — rotenone PD BDNF/CREB — PMID 32479847
• Kuo et al. 2011 — TBI angiogenesis / neurogenesis — PMID 21427621

Preclinical therapeutic — pain / spinal

• Peterson et al. 2023 — spinal agmatine gene therapy for chronic pain — PMID 36710491
• Wade et al. 2008 — supraspinal agmatine attenuates fentanyl self-administration — PMID 18495108
• Fairbanks group 2016 — morphine tolerance prevention — PMID 27774136

Gut / microbiome / 2024+ novel mechanisms

• Yun et al. 2024, Nat Metab — microbial agmatine / FXR / PCOS ADVERSE signal — PMID 38769396
• Lu et al. 2024, Gut Microbes — colorectal cancer Wnt/β-catenin ADVERSE signal — PMID 38706224
• Zhang et al. 2024, Biomed Pharmacother — ulcerative colitis macrophage repolarization BENEFIT — PMID 39413617
• Li et al. 2025 — de novo polyamine synthesis gut microbiome IBD — PMID 39924644

Eye / glaucoma

• Hong et al. 2010 — topical agmatine ↓ IOP in rat — PMID 19782071

Epilepsy / seizures

• Li et al. 2021 — pyroptosis inhibition — PMID 34421582
• Xu et al. 2014 — high-dose PTZ seizure amelioration — PMID 24944600

Cardiovascular

• Raasch et al. 2002 — does NOT antagonize clonidine hypotension — PMID 11834614

Depression synergy / pharmacology

• Neis et al. 2018 — agmatine vs ketamine vs fluoxetine CUMS — PMID 30125592
• Tavares et al. 2018 — sub-threshold ketamine potentiation via mTOR/S6K — PMID 29763645
• Zomkowski et al. 2013 — lithium synergy forced swim — PMID 28178624

Sex-specific

• Uzbay 2010 — sex-related agmatine-caffeine interaction — PMID 20035742
• Zhang et al. 2021 — estrous cycle brain arginine metabolism — PMID 34245369
• Wellmann 2010 — female rat pup neonatal ethanol USV — PMID 19945529
• Hassanshahi 2023 — maternal stress offspring cognition — PMID 37269159

Transporter

• Molderings et al. 2003 — agmatine-specific cationic transporter human cells — PMID 15028572